Search
Angiotensin II
go.drugbank.com/drugs/DB11842ApprovedInvestigationalAs distributive shock is the most common type of shock in the inpatient setting and affects up to one third of patients in the intensive care unit, the FDA determined that there is a need for treatment … in adults with septic or other distributive shock.
Apadamtase alfa
go.drugbank.com/drugs/DB15164ApprovedInvestigational[A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP. … metalloproteinase with a thrombospondin type 1 motif, member 13), which is responsible for cleaving large von Willebrand factor multimers and preventing the formation of microthrombi - this deficiency in
Amiloride
go.drugbank.com/drugs/DB00594ApprovedInvestigationalAmiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705) … This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct.
Synonyms: N-amidino-3,5-diamino-6-chloropyrazinecarboxamide, 3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamideDeutetrabenazine
go.drugbank.com/drugs/DB12161ApprovedInvestigationalIt was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets. … In clinical trials of patients with HD, 12 weeks of treatment of deutetrabenazine resulted in overall improvement in mean total maximal chorea scores and motor signs than placebo [A32046].
Satralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigationalSatralizumab was first approved for use in Canada in June 2020 for the treatment of AQP4 antibody-positive patients with NMOSD. … [A218551] It received subsequent approvals in Switzerland and Japan,[A218551] and was approved for use by the FDA in August 2020,[L15566] becoming the 3rd treatment to receive FDA approval for NMOSD (after
Products: ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML, ENSPRYNG 120 mg/1ml solution for injection in pre-filled syringeDitiocarb zinc
go.drugbank.com/drugs/DB14193ApprovedDitiocarb zinc, also known as Diethyldithiocarbamic acid zinc salt, is a known chelator for copper and zinc. It also a dermatological sensitizer and allergen.
Categories: Compounds used in a research, industrial, or household settingSynonyms: Zinc N,N-diethyldithiocarbamateFosamprenavir
go.drugbank.com/drugs/DB01319ApprovedInvestigationalFosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.
Digitoxin
go.drugbank.com/drugs/DB01396ApprovedWithdrawnA cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. … (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)
Categories: Compounds used in a research, industrial, or household settingDaridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigational[A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023. … [A244225] It was approved by the FDA on January 10, 2022, under the name QUVIVIQ.[L39660] as the second orexin receptor antagonist approved to treat insomnia following [suvorexant].
Cabotegravir
go.drugbank.com/drugs/DB11751ApprovedInvestigational[A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals. … [L31198] While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in